WELCOME TO FEMERIS Women’s Health Research Center

FEMERIS Women’s Health Research Center is a multi-discipline research center within Medical Diagnostic Laboratories, L.L.C.(MDL) dedicated to discovery and development of diagnostic biomarkers, therapeutic targets, and engineered probiotics in the detection and treatment of obstetric and gynecologic infectious diseases and medical conditions.

FEMERIS is a member of the Genesis Biotechnology Group ™ (GBG) located in Hamilton, New Jersey, and is easily accessible to other academic research and medical centers, biotech companies, and pharmaceutical companies in the New York/New Jersey/Pennsylvania area.

Our goal is to understand medical issues that affect women’s health and translate our research findings to advance clinical analytics, drug discovery, and ultimately leading to medical therapy.

We also serve as a resource for research collaborations and pre-clinical studies conducted by other members of GBG including MDL.

4/2012 - Announcing new testing for Aerobic Vaginitis

4/2012 - Announcing a Complimentary Reflex Test to Determine Metronidazole Resistance in Trichomonas vaginalis

1/2012 - FEMERIS scientist, Dr. David Hilbert, had a manuscript entitled "Clinical Escherichia coli isolates utilize alpha-hemolysin to inhibit in vitro epithelial cytokine production" accepted into the journal Microbes and Infection.

8/2011 - Announcing new Bacterial Vaginosis/Lactobacillus Profiling Assay

6/2011 - Femeris launches endometriosis research focusing on the discovery of new biomarkers for non-invasive diagnostics and validation of novel therapeutic targets for high-throughput small molecule inhibitor screening.

05/2011 - FEMERIS scientist, Dr. David Hilbert, will be presenting his research on the analysis of host antimicrobial protein production during bacterial vaginosis at the 112th American Society for Microbiology Conference in New Orleans, LA.

04/2011 - FEMERIS scientists will be attending the 2011 American College of Obstetrics and Gynecology conference in Washington D.C.

12/2010 - FEMERIS developed a Urinary Tract Infection Antibiotic Susceptibility assay for the Enterobacteriaceae Escherichia coli, Klebsiella spp., and Proteus mirabilis for Medical Diagnostic Laboratories.

11/2010 - FEMERIS scientist, Dr. Sergey Balashov, presented his research on Neisseria gonorrhoeae antibiotic susceptibility testing at the Association for Molecular Pathology Conference in San Jose, CA.

09/2010 - FEMERIS scientist, Dr. Scott Gygax, presented his research on Methicillin-Resistant Staphylococcus aureus at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston, MA.

WELCOME TO FEMERIS Women’s Health Research Center

Latest News